Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma.

The prognostic significance of Bcl-2 protein expression and bcl-2 gene rearrangement in diffuse large cell lymphomas (DLCL) is controversial. Bcl-2 protein expression prevents apoptosis and may have an important role in clinical drug resistance. The presence of a bcl-2 gene rearrangement in de novo DLCL suggests a possible follicle center cell origin and perhaps a distinct clinical behavior more akin to low-grade non-Hodgkin's lymphoma (NHL). The purpose of this study was to determine the impact of Bcl-2 protein expression and bcl-2 gene rearrangement (mbr and mcr) on survival of a cohort of patients with DLCL who were uniformly evaluated and treated with effective chemotherapy. Patients included the original MACOP-B cohort (n = 121) and the initial 18 patients treated with the VACOP-B regimen (total = 139). All patients had advanced-stage disease, were 16 to 70 years old, and corresponded to Working Formulation categories F, G, or H. No patients had prior treatment, discordant lymphoma, or human immunodeficiency virus seropositivity. Paraffin sections from diagnostic biopsies were analyzed for bcl-2 gene rearrangement including mbr and mcr breakpoints by polymerase chain reaction and Bcl-2 protein expression by immunohistochemistry. With a median follow-up of 81 months, overall (OS), disease-free (DFS), and relapse-free survival (RFS) were measured to determine the prognostic significance of these parameters. Analyzable DNA was present in 118 of 139 (85%) cases, with 14 demonstrating a bcl-2 rearrangement (11 mbr, 3 mcr). All 14 of these bcl-2 gene rearrangement-positive cases were found in the 102 patients with a B-cell immunophenotype, but the presence of this rearrangement had no significant influence on survival. Bcl-2 protein expression was interpretable in 116 of 139 (83%) cases, with immunopositivity detected in 54 of 116 (47%). Using a cut-off of greater than 10% Bcl-2 immunopositive tumor cells for analysis, positive Bcl-2 protein expression was seen in 28 of 116 (24%) patients and the presence of this expression correlated with decreased 8-year OS (34% v 60%, P < .01), DFS (32% v 66%, P < .001), and RFS (25% v 59%, P < .001). Bcl-2 protein expression remained significant in multivariate analysis that included the clinical international prognostic index factors and immunophenotype (P < .02). In conclusion, although bcl-2 gene rearrangement status could not be shown to have an impact on outcome, Bcl-2 protein expression is a strong significant predictor of OS, DFS, and RFS in DLCLs.

[1]  R. Warnke,et al.  Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. , 1988, The New England journal of medicine.

[2]  M. Kikuchi,et al.  Bcl-2 Gene and Prognosis of B-cell Lymphoma. , 1991, Leukemia & lymphoma.

[3]  R. Gascoyne,et al.  Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes. , 1994, The American journal of pathology.

[4]  K. Lennert,et al.  The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. , 1985, Blood.

[5]  C. Bloomfield,et al.  There are differences in cytogenetic abnormalities among histologic subtypes of the non-Hodgkin's lymphomas , 1985 .

[6]  J. Connors,et al.  Updated clinical experience with MACOP-B. , 1987, Seminars in hematology.

[7]  S. Poppema,et al.  Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: an analysis of 83 cases. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Connors,et al.  MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. , 1985, Annals of internal medicine.

[9]  D C Linch,et al.  Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. , 1996, Blood.

[10]  J Diebold,et al.  Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 1996, Blood.

[11]  K. A. Lee,et al.  Investigation of BCL-2 gene rearrangements in a United Kingdom series of low and high grade non-Hodgkin's lymphomas. , 1993, Leukemia & lymphoma.

[12]  John Calvin Reed,et al.  bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. , 1992, Cancer research.

[13]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[14]  T M Grogan,et al.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[15]  S. Korsmeyer,et al.  Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around Jh on chromosome 14 and near a transcriptional unit on 18 , 1985, Cell.

[16]  C. Borner.  Diminished Cell Proliferation Associated with the Death-protective Activity of Bcl-2* , 1996, The Journal of Biological Chemistry.

[17]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[18]  K. Kinzler,et al.  Paradoxical inhibition of solid tumor cell growth by bcl2. , 1994, Cancer research.

[19]  H. Petrie,et al.  Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death , 1996, The Journal of experimental medicine.

[20]  K. Mukai.  Large cell lymphoma. , 1989 .

[21]  B. Wilkes,et al.  The bcl-2 gene is rearranged in many diffuse B-cell lymphomas. , 1988, Blood.

[22]  John Calvin Reed,et al.  Somatic point mutations in the translocated bcl-2 genes of non-Hodgkin's lymphomas and lymphocytic leukemias: implications for mechanisms of tumor progression. , 1993, Leukemia & lymphoma.

[23]  W. Velasquez,et al.  The gene located at chromosome 18 band q21 is rearranged in uncultured diffuse lymphomas as well as follicular lymphomas. , 1987, Blood.

[24]  R. Gascoyne,et al.  Comparison of cytogenetic analysis, southern analysis, and polymerase chain reaction for the detection of t(14; 18) in follicular lymphoma. , 1995, American journal of clinical pathology.

[25]  N. Harris,et al.  bcl‐2 Rearrangements in de novo diffuse large cell lymphoma. Association with distinctive clinical features , 1993, Cancer.

[26]  John Calvin Reed,et al.  Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. , 1993, Blood.

[27]  John Calvin Reed,et al.  Frequent incidence of somatic mutations in translocated BCL2 oncogenes of non-Hodgkin's lymphomas. , 1992, Blood.

[28]  R. Warnke,et al.  Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene. , 1996, Blood.

[29]  M. Oken,et al.  bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. , 1989, The New England journal of medicine.

[30]  D. Mason,et al.  Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. , 1990, The American journal of pathology.

[31]  F. Cabanillas,et al.  The clinical relevance of t(14;18)/BCL-2 rearrangement and DEL 6q in diffuse large cell lymphoma and immunoblastic lymphoma. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  D.,et al.  Regression Models and Life-Tables , 2022 .

[33]  S. Proctor,et al.  The relationship between bcl‐2 expression and response to chemotherapy in acute leukaemia , 1994, British journal of haematology.

[34]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[35]  P. Nowell,et al.  Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. , 1984, Science.

[36]  D. Weisenburger,et al.  Correlation of secondary cytogenetic abnormalities with histologic appearance in non-Hodgkin's lymphomas bearing t(14;18)(q32;q21). , 1988, Journal of the National Cancer Institute.

[37]  K. Offit,et al.  18q21 rearrangement in diffuse large cell lymphoma: incidence and clinical significance , 1989, British journal of haematology.

[38]  D. Mason,et al.  The 14;18 translocation in European cases of follicular lymphoma: comparison of Southern blotting and the polymerase chain reaction , 1990, British journal of haematology.

[39]  S. Jhanwar,et al.  Cytogenetic and histologic correlations in malignant lymphoma. , 1987, Blood.

[40]  J Hermans,et al.  Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. Piris,et al.  p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. , 1994, British Journal of Cancer.

[42]  A. Brun,et al.  Incidence and prognostic significance of t(14;18) translocation in follicle center cell lymphoma of low and high grade. A report from southern Sweden. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  D. Jong,et al.  Essential Differences in Oncogene Involvement Between Primary Nodal and Extranodal Large Cell Lymphoma , 1991 .

[44]  S. Korsmeyer,et al.  Refinement of lymphoma cytogenetics by the chromosome 18q21 major breakpoint region. , 1987, Blood.

[45]  J. Connors,et al.  MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[47]  T. Greiner,et al.  Nodular lymphocyte-predominant Hodgkin's disease associated with large-cell lymphoma: analysis of Ig gene rearrangements by V-J polymerase chain reaction. , 1996, Blood.

[48]  R. Warnke,et al.  Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. , 1987, The New England journal of medicine.

[49]  C. Bloomfield,et al.  Nonrandom chromosome abnormalities in lymphoma. , 1983, Cancer research.

[50]  C. Croce,et al.  The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. , 1985, Science.

[51]  M. Ladanyi,et al.  Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. , 1994, The New England journal of medicine.

[52]  H. Stein,et al.  Frequency and structure of t(14;18) major breakpoint regions in non-Hodgkin's lymphomas typed according to the Kiel classification: analysis by direct DNA sequencing. , 1991, Cancer research.

[53]  J. Magaud,et al.  High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. , 1993, Blood.

[54]  J. Sklar,et al.  Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[55]  G. Linette,et al.  Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.